Thread by @DrOlaLandgren

Here are my Top 10 #ASH21
@ASH_hematology myeloma abstracts.

Links to the full abstract. As in the past, I focus on scientific innovation and clinical high-impact studies.
@SylvesterCancer #mmsm @mtmdphd

Thread with countdown
👇

1) Prevalence of Smoldering Multiple Myeloma: Results from the Iceland Screens, Treats, or Prevents Multiple Myeloma (iStopMM) Study. ash.confex.com/ash/2021/webpr…
A game changer for the field, addressing the role of population screening.
#ASH21 @SylvesterCancer #mmsm @mtmdphd

2) Monoclonal Gammopathy of Undetermined Significance and COVID-19: Results from the Population-Based Iceland Screens Treats or Prevents Multiple Myeloma Study (iStopMM). ash.confex.com/ash/2021/webpr… Highly important information for individuals diagnosed with MGUS. #ASH21

3) Screening for Monoclonal Gammopathy of Undetermined Significance: A Population-Based Randomized Clinical Trial. First Results from the Iceland Screens, Treats, or Prevents Multiple Myeloma (iStopMM) Study. ash.confex.com/ash/2021/webpr… Game changer! #ASH21

4) Phase 1b Results for Subcutaneous Talquetamab Plus Daratumumab in Patients with Relapsed/Refractory Multiple Myeloma. ash.confex.com/ash/2021/webpr… Future directions = chemo-free therapy for myeloma patients. The beginning of the future! #ASH21

5) Genomic and Immune Signatures Predict Sustained MRD Negativity in Newly Diagnosed Multiple Myeloma Patients Treated with Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone (D-KRd). ash.confex.com/ash/2021/webpr… Cutting-edge translational science designed to find a cure #ASH21

6) Normalization of the Immune Microenvironment during Lenalidomide Maintenance Is Associated with Sustained MRD Negativity in Patients with Multiple Myeloma ash.confex.com/ash/2021/webpr… Normalization of immune microenvironment in patients with sustained MRD negativity: wow! #ASH21

7) Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd), Autologous Transplantation and MRD Response-Adapted Consolidation and Treatment Cessation. Final Primary Endpoint Analysis of the Master Trial ash.confex.com/ash/2021/webpr… Idea of treatment-free monitoring. #ASH21

8) Universal Updated Phase 1 Data Validates the Feasibility of Allogeneic Anti-BCMA ALLO-715 Therapy for Relapsed/Refractory Multiple Myeloma ash.confex.com/ash/2021/webpr… Strong data with off-the-shelf BCMA allogeneic CAR T cell therapy in myeloma. #ASH21

9) Phase I First-in-Class Trial of MCARH109, a G Protein Coupled Receptor Class C Group 5 Member D (GPRC5D) Targeted CAR T Cell Therapy in Patients with Relapsed or Refractory Multiple Myeloma ash.confex.com/ash/2021/webpr… CAR T cells targeting GPRC5D. Exciting! #ASH21

10) Updated Results from MajesTEC-1: Phase 1/2 Study of Teclistamab, a B-Cell Maturation Antigen x CD3 Bispecific Antibody, in Relapsed/Refractory Multiple Myeloma ash.confex.com/ash/2021/webpr… Strong results from BCMA-CD3 bispecific monoclonal SC antibody: great for patients! #ASH21